Director Sean Whelan filed a Form 4 with the SEC on November 17, 2026, disclosing the acquisition of Stock Appreciation Rights in Zomedica Corp., traded as ZOMDF, with a transaction date of November 16, 2026.
Key Highlights
- Reporting person: Sean Whelan, identified as a Director of Zomedica Corp.
- Security acquired: 1,975,033 Stock Appreciation Rights, acquired (transaction code A) on November 16, 2026.
- Exercise price: The conversion or exercise price of the derivative security is listed as $0.10.
- Price paid: The price of the derivative security at acquisition is listed as $0.
- Expiration date: The rights are exercisable beginning November 15, 2027, and expire November 15, 2036.
- Resulting ownership: Following the reported transaction, Whelan beneficially owns 1,975,033 Stock Appreciation Rights directly, with the underlying security being Common shares in the same amount.
Zomedica Director Sean Whelan's Stock Appreciation Right Grant, November 2026
According to the Form 4 filed on November 17, 2026, Sean Whelan, a Director of Zomedica Corp. (ZOMDF), reported the acquisition of 1,975,033 Stock Appreciation Rights on November 16, 2026. The filing identifies Whelan's address as 1101 Technology Drive, Suite 100, Ann Arbor, Michigan 48108, and indicates the form was filed by one reporting person.
The filing discloses the transaction in Table II, which covers derivative securities. The Stock Appreciation Rights carry a conversion or exercise price of $0.10, and the price of the derivative security at the time of acquisition is listed as $0. The rights become exercisable on November 15, 2027, and have an expiration date of November 15, 2036. The underlying security is listed as Common shares, with an amount of 1,975,033 shares. Following the transaction, Whelan's directly held derivative securities total 1,975,033 Stock Appreciation Rights, according to the filing.
No transactions were reported in Table I, which covers non-derivative securities. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, and no amendment date is listed, indicating this is an original filing. The Form 4 was signed by Sean Whelan and dated November 17, 2026.
What Was Disclosed
Sean Whelan, a Director at Zomedica Corp., disclosed the acquisition of 1,975,033 Stock Appreciation Rights on November 16, 2026, at an exercise price of $0.10, with no cost at acquisition, exercisable from November 15, 2027, through November 15, 2036.



Please wait processing your request...